drugset / Trial / NCT02553356
PT2385-102 Food Effect Study of PT2385 in Healthy Volunteers
Phase 1
Completed
16 enrolled
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
RandomizedCrossoverOpen-labelTreatment
Summary
This Phase 1, single-dose study will be conducted in adult female subjects (N = 16) who are in general good health and selected for participation in the study according to the selection criteria. This study will assess the effect of food on the pharmacokinetics of PT2385 Tablets. The study will consist of two periods and will be conducted in a crossover fashion.
Timeline
- Start
- 2015-09
- Primary completion
- 2015-11
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PT2385 | Small molecule | — | — |
Indications
No indication recorded.